Article 1 to 4 out of 4 concerning Inverness Medical Innovations Inc. (IMI)
BioCurex Licenses RECAF Technology to Inverness Medical Innovations(01/11/2008) BioCurex and Inverness Medical Innovations have announced a licensing agreement for BioCurex's RECAF material and technology. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most ...
Biosite Prepared to Enter Into Discussions With Inverness Medical Innovations(04/12/2007) Biosite Incorporated announced that its Board of Directors, after consultation with its financial and legal advisors, has determined that the acquisition proposal set forth in the letter received from Inverness Medical Innovations, Inc. on April 4, ...
ITI Life Sciences commits £30 million to new R&D programme(03/02/2005) New company - Stirling Medical Innovations - established to develop near-patient and home use diagnostic tests based on novel biomarker technologies ITI Life Sciences announced it has committed £30 million as part of a new three-year R&D programme focused on the development of new near-patient and home use diagnostic tests. Initially, the programme will focus on developing near-patient tests ...
Top
